Advances in Clinical and Molecular Myeloid Malignancies

Dear Colleagues,

Hematopoietic malignancies are often characterized by genetic mutations and epigenetic alterations that may lead to oncogenes activation or oncosuppressors inactivation, besides the non-genomic loss of function of crucial oncosuppressors. In recent years, the identification of new prognostic markers has overwhelmingly emerged as a powerful tool to approach the eradication of stem cell clones and as a valuable Swiss knife for monitoring minimal residual disease and relapse. Besides contributing to the molecular characterization of hematological disorders, the identification of malfunctioning players and related dysregulated signaling pathways has unveiled novel therapeutic targets. Indeed, as a readout of these discoveries, in the last decades there has been an increase in the number of compounds selectively acting on single molecules (e.g., kinases, IDH1 and 2, Bcl2 family members, and E3 ubiquitin ligases inhibitors) that are nowadays commonly used for the treatment of adult relapsed or refractory leukemia.

For this Special Issue, we are inviting researchers to submit original research articles or reviews  which address diverse aspects of the biology, clinical response to therapy, and molecular diagnostic and prognostic markers of myeloid disorders, including (Acute Myelocytic Leukemia) AML, Myelodysplastic syndromes (MDS), Myeloproliferative neoplasms (MPNs), and Chronic myelogenous leukemia (CML).

Prof. Cristina Panuzzo
Dr. Enrico Bracco
Dr. Barbara Pergolizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hematological malignancies
• oncosuppressors
• mutations
• prognostic markers
• molecular inhibitors